Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up After Gene-Modified Cell Therapy in Kite-Sponsored Studies
jRCT2013230062Recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2024
01
Overview
Open-label, single-arm trial in Non-hematologic malignancy and hematopoietic malignancies, sponsored by Gilead Sciences. Primary endpoints: Late-onset neurologic disorders possibly related to gene-modified cells, Late-onset autoimmune disorders possibly related to gene-modified cells and 4 more. Started Apr 2024; status: recruiting.
02
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on jRCT2013230062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013230062.